CVR 33871643Public limited company (A/S)Ikke-finansielle holdingselskaber (642120)København ØFounded 17 Aug 2011
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about CS MEDICA a/s, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, Jan 2026
-3 (-75%) over 12 months
Gross profit
634.4K
DKK, annual report 2025
-77.7% on 2024
Result
-12.6M
DKK, annual report 2025
Equity
-4.1M
DKK, annual report 2025
CoLund ApSCVR 25837010, 33.3% to under 50% of capital and votes
LHX Invest ApSCVR 41548460, 33.3% to under 50% of capital and votes
Group holding company
Dandex estimate: NACE 642120, no majority ownerLone Henriksensince 17 Aug 2011
Owners of 5% or more. CVR registers shares in bands, not exact figures. All notified 2 Aug 2020.
CVR 2583701033.3% to under 50% of capital and votessince 1 Aug 2020
CVR 4154846033.3% to under 50% of capital and votessince 1 Aug 2020
50% to under 66.7% of capital and votesnotified 2 Aug 202030 Sep 2015 to 1 Aug 2020
50% to under 66.7% of capital and votes30 Sep 2015 to 1 Aug 2020
2 Danish companies.
SubsidiaryCVR 33871902100% of capital and votes
SubsidiaryCVR 41183144100% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR. Subsidiary (datterselskab): 50% or more of the votes, a Dandex estimate; in the 50% band a joint venture is not ruled out.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Jan 2026, monthly: 1 employee, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 3 | 3 | 4 | 3 | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| FTE | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Jan 2026, published 28 Mar 2026.
Group figures (koncern) for 2021 to 2024, the company's own for 2025, in DKK, from the annual reports filed in XBRL.
2025, DKK: Revenue not reported, Gross profit 634.4K, Operating profit -3.8M, Result for the year -12.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 20.9M, Equity -4.1M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021group | 2022group | 2023group | 2024group | 2025 |
|---|---|---|---|---|---|
| Revenue | 3,180 | 10,583 | 1,067 | 8,075 | Not reported |
| Gross profit | Not reported | 4,621 | 914 | 2,849 | 634 |
| Operating profit | -176 | -13,334 | -17,899 | -12,485 | -3,753 |
| Result for the year | +648 | -10,803 | -14,513 | -9,651 | -12,553 |
| Equity | 24,147 | 24,927 | 10,414 | 6,016 | -4,068 |
| Total assets | 27,411 | 27,906 | 25,855 | 36,380 | 20,934 |
| Employees (average) | 4 | Not reported | Not reported | Not reported | 3 |
Large listed filers report IFRS figures in an ESEF report, for the group where there is one.
Annual report 2025
1 Oct 2024 to 30 Sep 2025, published 10 Apr 2026
Annual report 2024
1 Oct 2023 to 30 Sep 2024, published 10 Apr 2025
Annual report 2023
1 Oct 2022 to 30 Sep 2023, published 17 Apr 2024
Annual report 2022
1 Oct 2021 to 30 Sep 2022, published 10 Mar 2023
Annual report 2021
1 Oct 2020 to 30 Sep 2021, published 28 Dec 2021
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
Group figures (koncern) for 2021 to 2024, the company's own for 2025, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2021group | 2022group | 2023group | 2024group | 2025 |
|---|---|---|---|---|---|
| Revenue growth (omsætningsvækst) | 50.6% | 232.9% | -89.9% | 656.6% | Not reported |
| EBIT margin (overskudsgrad) | -5.5% | -126% | -1,677% | -154.6% | Not reported |
| EBITDA | 1,191 | -11,258 | -15,823 | -10,369 | -2,965 |
| EBITDA margin (EBITDA-margin) | 37.5% | -106.4% | -1,482.5% | -128.4% | Not reported |
| Employee growth (vækst i antal ansatte) | 100% | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 10,693note 2 | Not reportednote 3 | Not reportednote 3 | Not reportednote 3 | 1,166note 2 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
What Pro holds for CS MEDICA a/s:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseDebt conversionPaid in 2,506,495 | None | 2,506,495 | None | 1,236,732 | |
| IncreaseDebt conversionPaid in 4,927,318 | None | 4,927,318 | None | 1,113,179 | |
| IncreaseCash, debt conversionPaid in 6,637,980, cash price 46.15, implied value 41,415,782 | 46.15 | 6,637,980 | 41,415,782 | 897,343 | |
| IncreaseCashPaid in 9,907,615, cash price 143.08, implied value 114,600,488 | 143.08 | 9,907,615 | 114,600,488 | 800,971 | |
| IncreaseNot read from the announcement | None | None | None | 731,725 | |
| IncreaseCashPaid in 850,000, cash price 130.77, implied value 93,516,978 | 130.77 | 850,000 | 93,516,978 | 715,130 | |
| IncreaseCash, debt conversionPaid in 22,345,393, cash price 118.46, implied value 83,945,373 | 118.46 | 22,345,393 | 83,945,373 | 708,630 | |
| IncreaseContribution in kind, bonus issue from reservesPaid in 4,826,920 | None | 4,826,920 | None | 520,000 |
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingCashPaid in 80,000 | None | 80,000 | None | 80,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital. 1 step could not be read that way and stand as registered.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
32 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: c/o Lone Henriksen, Indiakaj 10, 2., 2100 København Ø
Ny kommune: København
Vedtægter ændret: 01.06.2025
Kapitalforhøjelsen er besluttet den 01.06.2025.
kr. 123.553,61, indbetalt ved konvertering af gæld, kurs 2.028,67.
Kapitalen udgør herefter kr. 1.236.732,34.
Ny adresse: c/o Lone Henriksen, Kongevejen 120, Lønholt, 3480 Fredensborg
Ny kommune: Fredensborg
Bestyrelse:
Fratrådte:
Mads Verner Jørgensen, den 10.04.2025.
Vedtægter ændret: 28.03.2025
Bestyrelse:
Fratrådte:
Jesper Herold Halle, den 28.03.2025, Flemming Heegaard, (formand), den 28.03.2025, Ib Madsen, den 28.03.2025, Anders Permin, den 28.03.2025.
Tiltrådte:
Lone Henriksen, den 28.03.2025, Mads Verner Jørgensen, den 28.03.2025.
Vedtægter ændret: 12.11.2024
Kapitalforhøjelsen er besluttet den 12.11.2024.
kr. 215.835,89, indbetalt ved konvertering af gæld, kurs 2.282,90.
Kapitalen udgør herefter kr. 1.113.178,73.
Vedtægterne er yderligere ændret
Vedtægter ændret: 31.07.2024
Kapitalforhøjelsen er besluttet den 31.07.2024.
kr. 43.320,56, indbetalt ved konvertering af gæld, kurs 9.670,87.
Kapitalen udgør herefter kr. 897.342,84.
Vedtægter ændret: 31.07.2024
Kapitalforhøjelsen er besluttet den 31.07.2024.
kr. 32.446,00, indbetalt kontant, kurs 4.615,38. kr. 20.605,00, indbetalt ved konvertering af gæld, kurs 4.615,38.
Kapitalen udgør herefter kr. 854.022,28.
Bestyrelse:
Fratrådte:
Karsten Adelmark, den 29.02.2024, CEO Jørgen Flemming Ladefoged, (formand), den 29.02.2024.
Tiltrådte:
Jesper Herold Halle, den 29.02.2024, Flemming Heegaard, (formand), den 29.02.2024, Ib Madsen, den 29.02.2024.
Vedtægter ændret: 14.04.2023
Bestyrelse:
Fratrådte:
Alexandre Fevre, den 30.06.2023.
Ny adresse: Indiakaj 10, 2., 2100 København Ø
Bestyrelse:
Fratrådte:
Stein Arve Løkstad, den 14.02.2023.
Bestyrelse:
Fratrådte:
Bo Erik Lennart Unéus, den 25.10.2022.
Vedtægter ændret: 05.09.2022
Kapitalforhøjelsen er besluttet den 05.09.2022.
kr. 69.246,78, indbetalt kontant, kurs 14.307,69.
Kapitalen udgør herefter kr. 800.971,28.
Vedtægterne er yderligere ændret
Vedtægter ændret: 31.08.2022
Kapitalnedsættelse besluttet 31.08.2022 og gennemført 01.09.2022 dækning af underskud kr. ,50 til kurs 100,00.
Kapitalen udgør herefter kr. 731.724,50.
Vedtægter ændret: 31.08.2022
Kapitalforhøjelsen er besluttet den 31.08.2022.
kr. 16.595,00, indbetalt kontant, kurs 15.845,68.
Kapitalen udgør herefter kr. 731.725,00.
Vedtægter ændret: 03.02.2022
Kapitalforhøjelsen er besluttet den 03.02.2022.
kr. 6.500,00, indbetalt kontant, kurs 13.076,92.
Kapitalen udgør herefter kr. 715.130,00.
Bestyrelse:
Tiltrådte:
Alexandre Fevre, den 03.02.2022.
Vedtægter ændret: 09.12.2021
Nyt navn: CS MEDICA a/s
Selskabet tegnes af den administrerende direktør i forening med et bestyrelsesmedlem, af tre medlemmer af bestyrelsen eller af den samlede bestyrelse.
Vedtægter ændret: 07.09.2021
Kapitalforhøjelsen er besluttet den 07.09.2021.
kr. 125.213,73, indbetalt kontant, kurs 11.846,15. kr. 63.416,27, indbetalt ved konvertering af gæld, kurs 11.846,15.
Kapitalen udgør herefter kr. 708.630,00.
Bestyrelse:
Fratrådte:
Gitte Henriksen, (formand), den 01.07.2021, CEO Jørgen Flemming Ladefoged, den 01.07.2021.
Tiltrådte:
Gitte Henriksen, den 01.07.2021, CEO Jørgen Flemming Ladefoged, (formand), den 01.07.2021.
Vedtægterne er yderligere ændret
Vedtægter ændret: 16.04.2021
Selskabet tegnes af den administrerende direktør i forening med formanden, af fire medlemmer af bestyrelsen eller af formanden i forening med to bestyrelsesmedlemmer.
Virksomheden er omdannet til et aktieselskab med CVR-NR. 33871643
Vedtægterne er yderligere ændret
Vedtægter ændret: 16.04.2021
Nyt navn: CS medica a/s
Bestyrelse:
Fratrådte:
Gitte Henriksen, den 16.04.2021.
Tiltrådte:
Gitte Henriksen, (formand), den 16.04.2021, Stein Arve Løkstad, den 16.04.2021, Bo Erik Lennart Unéus, den 16.04.2021.
Direktion:
Fratrådte:
Gitte Henriksen, (adm. dir), den 16.04.2021.
Tiltrådte:
Lone Henriksen, (adm. dir), den 16.04.2021.
Vedtægter ændret: 16.04.2021
Nyt navn: CS medico ApS
Ny adresse: Fruebjergvej 3, 2100 København Ø
Ny kommune: København
Kapitalforhøjelsen er besluttet den 16.04.2021.
kr. 6.755,00, indbetalt i værdier, kurs 71.457,00. kr. 433.245,00, indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 520.000,00.
Bestyrelse:
Fratrådte:
Lone Henriksen, (formand), den 16.04.2021.
Tiltrådte:
CEO Jørgen Flemming Ladefoged, den 16.04.2021, Anders Permin, den 16.04.2021.
Formål ændret: Selskabets formål er at drive medicinalvirksomhed og hermed forbundet virksomhed.
Ny adresse: Korskildelund 6, 2670 Greve
Bestyrelse:
Tiltrådte:
Lone Henriksen, (formand), den 24.07.2020.
Direktion:
Fratrådte:
Lone Henriksen, den 24.07.2020.
Bestyrelse:
Tiltrådte:
Gitte Henriksen, den 24.07.2020.
Direktion:
Tiltrådte:
Gitte Henriksen, (adm. dir), den 24.07.2020.
Vedtægter ændret: 24.07.2020
Nyt navn: CS Group ApS
Revision:
Fratrådte:
Pryds Statsautoriseret Revisionsfirma, den 27.02.2020.
Tiltrådte:
CVR-NR. 15915641 CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB, Store Kongensgade 68, 1264 København K, den 27.02.2020.
Stiftelsesdato:
17.08.2011.
Seneste vedtægtsdato:
17.08.2011.
Kapital:
kr. 80.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 80.000,00 til kurs 100,00.
Stifter:
Lone Henriksen, den 17.08.2011.
Direktion:
Lone Henriksen, den 17.08.2011.
Selskabet tegnes af ejeren.
Revision:
Pryds Statsautoriseret Revisions- firma, 3450 Allerød, den 17.08.2011.
Første regnskabsår:
17.08.2011 - 30.09.2012.
Regnskabsår:
01.10 - 30.09.
P-number 1017067105Indiakaj 10, 2100 København Ø